ARTICLE | Product Development

Verve for HERV

Why Servier picked GeNeuro's GNbAC1 for entry into multiple sclerosis

December 8, 2014 8:00 AM UTC

Servier could make its first foray into multiple sclerosis via an option deal with GeNeuro S.A. that it hopes will yield the first therapy targeted at a cause of the disease.

Last week Servier agreed to pay $47 million to GeNeuro for an option to license GNbAC1 to treat MS outside of the U.S. and Japan after GeNeuro completes a Phase IIb trial of the humanized mAb targeting the envelope protein of human endogenous retrovirus type W (HERV-W). Servier also has an option to take an undisclosed minority equity stake in GeNeuro within 12 months...